B
Bull
Bull · 25%ONC
$405.21
Precio del escenario
$359.580
-7.012 (-1.95%)Al cierre
Loading chart…
- High
- 361.030
- Open
- 356.500
- VWAP
- 357.82
- Vol
- 346.05K
- Mkt Cap
- —
- Low
- 352.860
- Amount
- 123.83M
- EV/EBITDA, TTM
- 19.97
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
AI analysis of BeOne Medicines AG (ONC)
buyBeigene, Ltd. (ONC) appears to be a good buy right now due to its strong revenue growth and positive earnings report. The current price is $366.73, and the company reported a Q2 revenue of $1.7 billion, which is a 28.8% year-over-year increase. Additionally, the gross margin is impressive at 89.76%, indicating strong profitability. The main risk is the high forward P/E ratio of 48.31, which suggests that the stock may be overvalued if growth does not continue as expected.
Métricas de valoración
The current forward P/E ratio for BeOne Medicines AG (ONC) is 48.31, compared to its 5-year average forward P/E of 67.34.
Alphio AI Price Scenarios for ONC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ONC
Cronología de eventos
Noticias
9.008-31Yahoo FinancePositive Results from HERIZON-GEA-01 Trial for HER2+ GEA
7.508-31stocktwitsNine Drugmakers Strike Deals with Trump Administration
7.508-31NewsfilterBeOne Partners with U.S. Government to Enhance Patient Access to Cancer Medicines
5.008-25stocktwitsFDA Approves Ziihera, Jazz Pharmaceuticals Hits All-Time High
- 8.508-25Newsfilter
FDA Approves TEVIMBRA with ZIIHERA for HER2+ GEA Treatment
ONC FAQ — answered by Alphio AI
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others. It operates in the Healthcare sector.
Beigene, Ltd. (ONC) appears to be a good buy right now due to its strong revenue growth and positive earnings report. The current price is $366.73, and the company reported a Q2 revenue of $1.7 billion, which is a 28.8% year-over-year increase. Additionally, the gross margin is impressive at 89.76%, indicating strong profitability. The main risk is the high forward P/E ratio of 48.31, which suggests that the stock may be overvalued if growth does not continue as expected.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.